The timely and cost-efficient manufacturing of cell and gene therapies is expected to be key to their commercial success, and Catalent Inc.’s acquisition of MaSTherCell SA indicates a desire to build its manufacturing operations in these areas.
Catalent is acquiring 240-employee MaSTherCell for $315m in an all-cash transaction from its owners, the NASDAQ-quoted [Orgenesis Inc.], of which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?